Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma

PURPOSE: The phase Ib/II open-label study (NCT01992653) evaluated the antibody-drug conjugate polatuzumab vedotin (pola) plus rituximab/obinutuzumab, cyclophosphamide, doxorubicin, and prednisone (R/G-CHP) as first-line therapy for B-cell non-Hodgkin lymphoma (B-NHL). We report the pharmacokinetics...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Cancer Chemother Pharmacol
Main Authors: Shemesh, Colby S., Agarwal, Priya, Lu, Tong, Lee, Calvin, Dere, Randall C., Li, Xiaobin, Li, Chunze, Jin, Jin Y., Girish, Sandhya, Miles, Dale, Lu, Dan
Format: Artigo
Sprog:Inglês
Udgivet: Springer Berlin Heidelberg 2020
Fag:
Original Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7188703/
https://ncbi.nlm.nih.gov/pubmed/32222808
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-020-04054-8
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker